BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33984677)

  • 1. Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study.
    Oki E; Watanabe J; Sato T; Kagawa Y; Kuboki Y; Ikeda M; Ueno H; Kato T; Kusumoto T; Masuishi T; Yamaguchi K; Kanazawa A; Nishina T; Uetake H; Yamanaka T; Yoshino T
    ESMO Open; 2021 Jun; 6(3):100146. PubMed ID: 33984677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
    Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
    Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
    Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
    Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
    Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
    Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
    Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
    Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
    Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
    J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
    Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
    BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
    Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
    Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
    Zeng Y; Gao W; Lin L; Chen X; Shen K
    J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
    Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
    PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer.
    Renfro LA; Zhang N; Lopatin M; Chao C; Alberts SR
    Clin Colorectal Cancer; 2017 Mar; 16(1):23-30. PubMed ID: 27600983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.